Public Meeting on Patient-Focused Drug Development for Autism

On May 4, 2017, FDA is conducting a public meeting on Patient-Focused Drug Development (PFDD) for Autism. FDA is interested in obtaining patient perspectives on the impact of autism on daily life and patient views on treatment approaches.

Date:

May 4, 2017

Time:

1:00 p.m. - 5:00 p.m.

Location:

FDA White Oak Campus
10903 New Hampshire Ave.
Building 31, Room 1503 B and C (Great Room)
Silver Spring, MD 20993
(Information about arrival to FDA’s White Oak campus)

Registration:

To register for this meeting, visit: Public Meeting on Patient-Focused Drug Development for Autism.

We recommend registering early for the meeting.

Webcast Information:

Patient-Focused Drug Development Meeting for Autism 

Public Docket:

In addition to providing input at the public meeting, stakeholders are invited to provide their perspectives on the discussion questions through the public docket. The docket closes on July 5, 2017.

• FDA is interested in patient responses to the questions listed in the Federal Register Notice.

• Access the public docket here: Docket Information

Meeting Information

• Webinar: Background on FDA and Patient-Focused Drug Development
• Meeting Agenda
• Autism Patient Focused Drug Development Meeting Slides
• Meeting Recording 1
• Meeting Recording 2
• Transcript
• The Voice of The Patient: Autism

Related Information

• Patient-Focused Drug Development: Disease Area Meetings Planned for Fiscal Years 2013-2017
• Enhancing Benefit-Risk Assessment in Regulatory Decision-Making